Retour aux projets

13385.1;4 PFFLR-LS

A novel antibody based therapy for allergy

Résumé

A novel antibody based therapy for allergy

Textes supplémentaires

Abstract

We intend to develop bispecific antibodies that target specifically IgE bearing B cells. Such bispecific antibodies will be evaluated for their capacity to inhibit IgE synthesis as well as to knock out IgE bearing B cells. The development of such antibodies represent an innovative approach as current therapeutic IgE-specific antibodies do not affect IgE production and therefore must be given frequently to maintain sufficient suppression of serum IgE. Glenmark has developed the necessary expression systems for bispecific antibodies and has all license agreement to market such antibodies. The academic partner has the individual anti-IgE antibodies that will be used for the construction of bispecific antibodies and will perform the preclinical testing in order to decide which construct will be taken up in the production pipeline.

Participants

Monique Vogel

Kontaktperson

monique.vogel@iib.unibe.ch

Inselspital Bern Monique Vogel Sahlihaus 2 3010 Bern BE CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2012-03-31
Date de fin
2015-12-20
Coûts totaux approuvés
CHF 338216.00
Section
5 KTI
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T115 Medical technology 100.0%